30.09.2013 • NewsBayerOlivier BrandicourtPeople

Olivier Brandicourt Appointed as New CEO of Bayer Healthcare

Olivier Brandicourt (57) has been appointed Chairman of the Board of Management of Bayer HealthCare and member of the Bayer Executive Council effective November 1, 2013. Since March 2013, Professor Wolfgang Plischke has led Bayer HealthCare on an interim basis in addition to his existing duties as a Bayer AG Board Member.

"With Olivier Brandicourt we have found a strong leader with outstanding international experience and a successful track record in the healthcare industry. I am convinced that he can significantly contribute to the further growth of our healthcare business," said Bayer Group CEO Dr. Marijn Dekkers.

Brandicourt has 25 years of international experience in the pharmaceutical industry, including executive responsibilities in France, the United States, Canada and the United Kingdom. He has been a member of the Executive Leadership Team of Pfizer, New York, USA, for the last three years. Until recently he was president and general manager of the Emerging Markets and Established Products Business Units. Before that he held senior operational positions as President of the Global Specialty Business Unit, and until 2012 he was head of the Global Primary Care Business Unit. Furthermore, he previously held senior regional and country management positions at Pfizer and positions across a range of disciplines including medical and marketing at Warner-Lambert/Parke-Davis.

"I am looking forward to joining the Bayer team. With a clear focus on research and development as well as a passion and dedication to improving people's lives, Bayer has an excellent track record in bringing innovation to the market," said Olivier Brandicourt.

Olivier Brandicourt holds a medical degree with a subspecialty in infectious diseases and tropical medicine, as well as a master's degree in biology from Paris 12 University, France. After completing his studies, Brandicourt spent two years in the Republic of Congo as a doctor and eight years with the Institute for Infectious and Tropical Diseases at Pitié-Salpêtrière Hospital in Paris, spending half this time in West and Central Africa working on malaria research. Brandicourt is an Honorary Fellow of the Royal College of Physicians in London, UK, and a member of the Children's Aid Society's Board of Trustees in New York. He is married with three grown-up children. 

 

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.